Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Agile Therapeutics Inc. AGRX

Alternate Symbol(s):  AGXRW

Agile Therapeutics Inc is a women's healthcare company to fulfill the unmet health needs of women. Its product candidates are designed to provide women with contraceptive options. The firm's initial product, Twirla, (levonorgestrel and ethinyl estradiol) transdermal system is a non-daily prescription contraceptive. Twirla is based on proprietary transdermal patch technology, called Skinfusion, which is designed to allow drug delivery through the skin.


Recent & Breaking News (NDAQ:AGRX)

Mid-Afternoon Market Update: Applied Materials Falls On Weak Sales Forecast; Quotient Shares Spike Higher

Benzinga.com  May 18, 2018

Mid-Day Market Update: Shineco Rises After Q3 Results; Campbell Soup Shares Slide

Benzinga.com  May 18, 2018

Mid-Morning Market Update: Markets Mixed; Deere Misses Q2 Estimates

Benzinga.com  May 18, 2018

Consolidated Research: 2018 Summary Expectations for Verint, Mesabi Trust, Clearwater Paper, Agile Therapeutics, Community Trust, and Layne Christensen — Fundamental Analysis, Key Performance Indications

GlobeNewswire May 18, 2018

Agile Therapeutics, Inc. Provides Regulatory Update on Twirla® (AG200-15) for the Prevention of Pregnancy

GlobeNewswire May 18, 2018

Agile Therapeutics Reports First Quarter 2018 Financial Results

GlobeNewswire May 7, 2018

Agile Therapeutics to Host First Analyst Day on October 10, 2017

GlobeNewswire October 2, 2017

Agile Therapeutics to Present Additional Phase 3 Data at the North American Forum on Family Planning Annual Meeting

GlobeNewswire September 28, 2017

Agile Therapeutics to Present at the Cantor Fitzgerald Global Healthcare Conference

GlobeNewswire September 14, 2017

Agile Therapeutics to Present Additional Phase 3 Data at the 73rd Annual Congress of the American Society for Reproductive Medicine

GlobeNewswire September 7, 2017

Agile Therapeutics to Present at the Rodman & Renshaw 19th Annual Global Investment Conference

GlobeNewswire August 22, 2017

Agile Therapeutics to Present at Liolios 6th Annual Gateway Conference

GlobeNewswire August 16, 2017

Agile Therapeutics Announces Pricing of Its Public Offering of Common Stock

GlobeNewswire August 3, 2017

Agile Therapeutics Announces Proposed Offering of Common Stock

GlobeNewswire August 2, 2017

Agile Therapeutics Reports Second Quarter 2017 Financial Results

GlobeNewswire July 28, 2017

Agile Therapeutics Announces FDA Acceptance of the NDA Resubmission of Twirla®

GlobeNewswire July 27, 2017

Agile Therapeutics Resubmits New Drug Application (NDA) for its Transdermal Contraceptive Patch, Twirla®

GlobeNewswire June 27, 2017

22 Stocks Moving In Friday's Pre-Market Session

Benzinga.com  June 16, 2017

Agile Therapeutics Reports First Quarter 2017 Financial Results

GlobeNewswire May 8, 2017

Agile Therapeutics Reports Additional Phase 3 SECURE Study Results Relating to Twirla® at ACOG 2017

GlobeNewswire May 6, 2017